The Association of the British Pharmaceutical Industry is working closely with the Department of Health and the NHS on how our members can best support the Government as plans evolve and we adapt to an ever-changing situation.
This COVID-19 hub gives you access to the most up-to-date information for what pharmaceutical companies are doing to tackle the outbreak.
We represent companies at the cutting-edge of science whose mission is to tackle the world’s healthcare challenges. Our members are in a unique position to respond to the COVID-19 outbreak and are already turning their knowledge, resources and experience to developing diagnostics and treatments for the disease.
Pharmaceutical companies have worked to combat a range of infectious diseases such as MERS, SARS, Ebola and influenza. COVID-19 is a new challenge.
At the middle of March, there are more than 320 medicines in various stages of development. (Source: Milken Institute)
Meanwhile there are more than 80 vaccines in clinical development, and 182 more in pre-clinical. (Source: World Health Organisation)
Find out more about what pharmaceutical companies are doing to tackle the disease.
As well as working with health authorities and regulators to create the medicines and vaccines that are needed, we’re also working with the Government to mitigate the impact that coronavirus may have on our everyday activities.
Our members are not currently reporting any concerns about shortages of medicines that relate to the loss of manufacturing capacity as a result of COVID–19 restrictions.
There are robust procedures in place to manage the supply of medicines in the UK, and companies will be taking all possible measures to secure supply for patients - in line with Government guidance.
Find out more about how pharmaceutical companies are managing any impact on their supply chains.
Dr Richard Torbett, Chief Executive of the Association of the British Pharmaceutical Industry. Read more.
